Core ADHD Symptom Improvement With Atomoxetine Versus Methylphenidate: A Direct Comparison Meta-Analysis
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Objective: Previous studies comparing atomoxetine and methylphenidate to treat ADHD symptoms have been equivocal. This noninferiority meta-analysis compared core ADHD symptom response between atomoxetine and methylphenidate in children and adolescents. Method: Selection criteria included randomized, controlled design; duration 6 weeks; and assessment of ADHD Rating Scale–IV–Parent Version: Investigator Administered and Scored (ADHDRS) scores. Six-week response rates, defined as ≥40% reduction in ADHDRS total score, were compared using a noninferiority margin of −15%. Results: Seven studies met inclusion criteria ( N = 1,368). After 6 weeks, 53.6% (95% confidence interval [CI] 48.6%-58.4%) of atomoxetine-treated patients ( n = 811) had responded compared with 54.4% (47.6%-61.1%) for methylphenidate ( n = 557), with atomoxetine demonstrating noninferiority to methylphenidate (absolute difference −0.9%, 95% CI −9.2%-7.5%). Conclusion: After 6 weeks of treatment atomoxetine and methylphenidate had comparable efficacy in reducing core ADHD symptoms in children and adolescents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The worldwide prevalence of ADHD: a systematic review and metaregression analysis
Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.942 · Cited by 5,346
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885 · cited 1×
“The absolute difference observed in the fixed effects model, when presented as a number needed to treat (NNT) (Altman, 1998; Cook & Sackett, 1995) indicates that on average 112 patients (95% CI −14 to ∞ to 11) need to be treated with methylphenidate instead of atomoxetine to achieve one additional…”
Backgroundmeta-analysis bias in location and selection of studies
Egger, M., & Smith, G. D. (1998) · BMJ · doi:10.1136/bmj.316.7124.61 · Cited by 1,374 · cited 1×
“The presence of publication bias in medical literature and its detrimental effect on the validity of meta-analysis results is a known problem (Egger & Smith, 1998).”
BackgroundBymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Confidence intervals for the number needed to treat.
Altman, D. G. (1998) · BMJ · doi:10.1136/bmj.317.7168.1309 · Cited by 938 · cited 2×
“The absolute difference observed in the fixed effects model, when presented as a number needed to treat (NNT) (Altman, 1998; Cook & Sackett, 1995) indicates that on average 112 patients (95% CI −14 to ∞ to 11) need to be treated with methylphenidate instead of atomoxetine to achieve one additional…”
BackgroundMichelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599 · cited 7×
“From a clinical perspective, taking into account other comparative advantages of atomoxetine in a broader context beyond response (Geller et al., 2007; Kelsey et al., 2004; Michelson et al., 2002; Sangal et al., 2006; Spencer et al., 2008), it was felt that a noninferiority margin of −15% would be judged acceptable in…”
BackgroundInfluentialKelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., Sutton, V. K., Gonzales, J., Malcolm, S. K., Schuh, K. J., et al. (2004) · Pediatrics · doi:10.1542/peds.114.1.e1 · Cited by 464 · cited 2×
“Conversely, atomoxetine cannot be used for immediate effect but has demonstrated coverage of ADHD symptoms in children and adolescents that continues to the following morning (Kelsey et al., 2004; Michelson et al., 2002).”
BackgroundPLISZKA, S. R., CRISMON, M. L., HUGHES, C. W., CORNERS, C. K., EMSLIE, G. J., JENSEN, P. S., McCRACKEN, J. T., SWANSON, J. M., & LOPEZ, M. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000215326.51175.eb · Cited by 442
Pelham, W. E., Gnagy, E. M., Burrows-Maclean, L., Williams, A., Fabiano, G. A., Morrisey, S. M., Chronis, A. M., Forehand, G. L., Nguyen, C. A., Hoffman, M. T., et al. (2001) · Pediatrics · doi:10.1542/peds.107.6.e105 · Cited by 378 · cited 1×
“All OROS methylphenidate doses were converted to IR equivalent (Pelham et al., 2001) for this analysis.”
MethodNewcorn, J. H., Kratochvil, C. J., Allen, A. J., Casat, C. D., Ruff, D. D., Moore, R. J., Michelson, D., & Atomoxetine/Methylphenidate Comparative Study Group (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.05091676 · Cited by 336 · cited 9×
“…Multicenter, double-blind, randomized 6-16 ATX 162 20 to 80 QD 8 Comparison of response rates derived from ADHDRS total scores MPH 164 5 to 20 BID Newcorn et al. (2008), LYBI Multicenter, double-blind, randomized 6-16 ATX 212 10 to 80 BID 6 Comparison of response rates (>40% improvement in…”
BackgroundMethodResultInfluentialSpencer, T., Heiligenstein, J. H., Biederman, J., Faries, D. E., Kratochvil, C. J., Conners, C. K., & Potter, W. Z. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1209 · Cited by 333 · cited 12×
“Although methylphenidate was included as a treatment arm in the Phase II studies conducted by Spencer et al. (2002), analyses directly comparing the efficacy of methylphenidate and atomoxetine were not reported.”
BackgroundMethodResultInfluentialKRATOCHVIL, C. J., HEILIGENSTEIN, J. H., DITTMANN, R., SPENCER, T. J., BIEDERMAN, J., WERNICKE, J., NEWCORN, J. H., CASAT, C., MILTON, D., & MICHELSON, D. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200207000-00008 · Cited by 292 · cited 10×
“The Prasad et al. (2007) and Kratochvil et al. (2002) studies were open label.”
BackgroundMethodResultInfluentialEffects of Atomoxetine and Methylphenidate on Sleep in Children With ADHD
Sangal, R. B., Owens, J., Allen, A. J., Sutton, V., Schuh, K., & Kelsey, D. (2006) · Sleep · doi:10.1093/sleep/29.12.1573 · Cited by 214 · cited 12×
“…HFBE Multicenter, open-labelb, randomized M: 7-16 ATX 178 5 to 90 BID 10 Comparison of distributions of days to relapse F: 7-9 MPH 40 5 to 60 BID Sangal et al. (2006), LYAV Multicenter, double-blind, order-randomized cross-overc 6-15 ATX 43 7.5 to 50 BID 6 Change from baseline to endpoint in…”
BackgroundMethodResultInfluentialRemission versus response as the goal of therapy in ADHD: A new standard for the field?
Steele, M., Jensen, P. S., & Quinn, D. M. P. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.006 · Cited by 174 · cited 1×
“In comparison, patients who meet CGI-ADHD-S remission criteria (score of 1 or 2) either no longer meet syndromal criteria or are virtually asymptomatic (Steele et al., 2006).”
BackgroundKemner, J. E., Starr, H. L., Ciccone, P. E., Hooper-Wood, C. G., & Crockett, R. S. (2005) · Advances in Therapy · doi:10.1007/bf02849870 · Cited by 99 · cited 2×
“As expected, the ≥40% improvement in ADHDRS total score response criteria resulted in lower estimates of response to either methylphenidate or atomoxetine than studies that have used less stringent criteria (Kemner et al., 2005; Pliszka et al., 2006).”
ResultAtomoxetine Treatment of ADHD in Children With Comorbid Tourette Syndrome
Spencer, T. J., Sallee, F. R., Gilbert, D. L., Dunn, D. W., McCracken, J. T., Coffey, B. J., Budman, C. L., Ricardi, R. K., Leonard, H. L., Allen, A. J., et al. (2008) · Journal of Attention Disorders · doi:10.1177/1087054707306109 · Cited by 98
Prasad, S., Harpin, V., Poole, L., Zeitlin, H., Jamdar, S., Puvanendran, K., & on behalf of the SUNBEAM Study Group (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167309 · Cited by 97 · cited 11×
“The Prasad et al. (2007) and Kratochvil et al. (2002) studies were open label.”
BackgroundMethodResultInfluentialWang, Y., Zheng, Y., Du, Y., Song, D. H., Shin, Y.-J., Cho, S. C., Kim, B. N., Ahn, D. H., Marquez-Caraveo, M. E., Gao, H., et al. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670601057767 · Cited by 84 · cited 5×
“Although several studies have been conducted in which methylphenidate has been compared to atomoxetine (Kratochvil et al., 2002; Newcorn et al., 2008; Prasad et al., 2007; Sangal et al., 2006; Spencer et al., 2002; Wang et al., 2007), the results have been equivocal.”
BackgroundMethodResultInfluential
Cited by
Sharma, A., & Couture, J. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028013510699 · Cited by 516
Philipsen, A., Jans, T., Graf, E., Matthies, S., Borel, P., Colla, M., Gentschow, L., Langner, D., Jacob, C., Groß-Lesch, S., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2146 · Cited by 175
Pharmacological and non-pharmacological treatment of adults with ADHD: A meta-review
De Crescenzo, F., Cortese, S., Adamo, N., & Janiri, L. (2017) · Evidence Based Mental Health · doi:10.1136/eb-2016-102415 · Cited by 150
Hanwella, R., Senanayake, M., & de Silva, V. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-176 · Cited by 137
Cubillo, A., Smith, A. B., Barrett, N., Giampietro, V., Brammer, M. J., Simmons, A., & Rubia, K. (2014) · Cerebral Cortex · doi:10.1093/cercor/bhs296 · Cited by 116
Metadata
- Authors
- Hazell, P. L., Kohn, M. R., Dickson, R., Walton, R. J., Granger, R. E., & van Wyk, G. W.
- Venue
- Journal of Attention Disorders
- Publisher
- SAGE Publications
- Published
- 2010-09-13
- Volume
- 15
- Issue
- 8
- Pages
- 674-683
- ISSN
- 1087-0547 (ISSN-L)
- 1557-1246
- OpenAlex
- W2048386311
- Cited by
- 65
- References
- 18
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.